10,618 Shares in Koninklijke Philips (NYSE:PHG) Bought by Atlas Capital Advisors LLC

Atlas Capital Advisors LLC bought a new stake in Koninklijke Philips (NYSE:PHG) during the second quarter, Holdings Channel.com reports. The firm bought 10,618 shares of the technology company’s stock, valued at approximately $268,000.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Principal Securities Inc. acquired a new stake in shares of Koninklijke Philips in the 4th quarter worth about $27,000. Allspring Global Investments Holdings LLC acquired a new stake in shares of Koninklijke Philips in the first quarter valued at approximately $40,000. Fifth Third Bancorp raised its holdings in shares of Koninklijke Philips by 34.4% during the first quarter. Fifth Third Bancorp now owns 3,008 shares of the technology company’s stock valued at $60,000 after buying an additional 770 shares during the last quarter. CWM LLC boosted its position in shares of Koninklijke Philips by 21.9% during the second quarter. CWM LLC now owns 3,429 shares of the technology company’s stock worth $86,000 after buying an additional 616 shares during the period. Finally, Blue Trust Inc. grew its holdings in Koninklijke Philips by 902.7% in the 2nd quarter. Blue Trust Inc. now owns 3,700 shares of the technology company’s stock worth $93,000 after buying an additional 3,331 shares in the last quarter. 13.67% of the stock is currently owned by institutional investors.

Koninklijke Philips Price Performance

PHG traded down $0.23 during trading on Friday, reaching $30.16. The stock had a trading volume of 559,145 shares, compared to its average volume of 1,014,496. The stock has a 50 day moving average of $27.48 and a two-hundred day moving average of $24.57. The company has a quick ratio of 0.74, a current ratio of 1.16 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $28.35 billion, a price-to-earnings ratio of -31.42, a price-to-earnings-growth ratio of 1.00 and a beta of 0.72. Koninklijke Philips has a 1-year low of $17.75 and a 1-year high of $30.71.

Koninklijke Philips (NYSE:PHG) last announced its quarterly earnings data on Monday, July 29th. The technology company reported $0.32 earnings per share for the quarter. The business had revenue of $4.80 billion during the quarter. Koninklijke Philips had a positive return on equity of 10.15% and a negative net margin of 2.35%. As a group, equities analysts anticipate that Koninklijke Philips will post 1.5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PHG has been the topic of several recent analyst reports. StockNews.com raised Koninklijke Philips from a “hold” rating to a “buy” rating in a research note on Monday, July 15th. Sanford C. Bernstein upgraded shares of Koninklijke Philips from a “market perform” rating to an “outperform” rating in a research note on Monday, May 13th. Finally, BNP Paribas raised shares of Koninklijke Philips from an “underperform” rating to a “neutral” rating in a research note on Tuesday, May 7th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold”.

Koninklijke Philips Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.